Circulation: Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis

Krishna J. Rocha-Sing , Sue Duval, Michael R. Jaff, Peter A. Schneider, Gary M. Ansel, Sean P. Lyden, Christopher M. Mullin, John P.A. Ioannidis, Sanjay Misra, Abraham R. Tzafriri, Elazer R. Edelman, Juan F. Granada, Christopher J. White, and Joshua A. Beckman. “Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis.”

Summary:
Paclitaxel-containing devices (PTXD) significantly reduce reintervention in patients with symptomatic femoropopliteal peripheral artery disease (PAD). A recent aggregate-data meta-analysis reported increased late mortality in PAD patients treated with PTXD. We performed an individual patient data (IPD) meta-analysis to evaluate mortality. This IPD meta-analysis, based on the most complete available data set of mortality events from PTXD randomized controlled trials, identified an absolute 4.6% increased mortality risk associated with PTXD use.

CIRCULATION, 6 May 2020, [Epub ahead of print] doi.org/10.1161/CIRCULATIONAHA.119.044697

May 6, 2020